Regional Summit on Acute Myeloid and Lymphocytic Leukemias

Oncology Meetings Innovations invites you to participate in our 2017 Regional Summit on Acute Myeloid and Acute Lymphoblastic Leukemia. In this summit, we will discuss the current treatment landscape for acute leukemia and how the latest approved therapies can be incorporated into clinical practice. Along with newly approved compounds, topics will also include compounds in late-stage development with emerging data for targeted maintenance therapies.

The meetings will consist of informative 15-minute presentations followed by group discussions of the current practice in AML and ALL. This Regional Summit assembles a distinguished group of key opinion leaders to present the leading strategies for employing the latest advances in treatment and emerging data on FLT-3, CD33 antibody drug conjugates, next-generation hypomethylating agents. Additionally, the audience will have the opportunity to engage the leading experts in discussion on their various topics and contribute to case-studies based on these new therapies. We look forward to welcoming you to our Regional Summits.

Confirmed Faculty

Chair: Dr. Richard Stone, MD. Dr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide. He is currently the Director of the Adult Acute Leukemia Program at DFCI, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B.

Tentative agenda subject to change:
7:00 AM - 7:55 AM Breakfast and registration
7:55 AM - 8:00 AM Welcome & introductions

New Cytotoxic Strategies for AML
8:00 AM - 8:20 AM Novel formulation of cytotoxic chemotherapy in AML
8:20 AM - 8:40 AM Antibody drug conjugates (CD33) in AML
8:40 AM - 9:00 AM Hypomethylating and demethylating agents in AML
9:00 AM - 9:20 AM Panel discussion and cases
9:20 AM - 9:40 AM Break

FLT-3 in AML
9:40 AM - 10:00 AM New advances in the biology of FLT3 (The midostaurin story)
10:00 AM - 10:20 AM Next-generation FLT3 inhibitors
10:20 AM - 10:40 AM Targeting FLT-3 mutations in combination with chemotherapy
10:40 AM - 11:00 AM Panel discussion and cases

New Targets in Development for AML
11:00 AM - 11:20 AM Inhibiting IDH1/2 in AML
11:20 AM - 11:40 AM Targeting BCL-2 in AML
11:40 AM - 12:00 PM Addressing toxicities associated with AML
12:00 PM - 12:30 PM Working Lunch

Emerging Therapies in ALL
12:30 PM - 12:50 PM ADC therapy in ALL
12:50 PM - 1:10 PM Harnessing T cells in ALL (CAR T cells and bispecific antibodies)
1:10 PM - 1:30 PM Current treatment of MPNs
1:30 PM - 1:50 PM Panel discussion and cases
1:50 PM - 2:00 PM Wrap Up and Adjourn





  • When

  • Saturday, October 14, 2017
    8:00 AM - 2:00 PM
    Eastern Time

  • Where

  • New York Marriott Downtown
    85 West St
    New York City, New York 10006
    (212) 385-4900

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!